Clinical Trials Logo

Clinical Trial Summary

Social anxiety disorder affects as many as 12% of Americans, resulting in significant distress and disability. Although exposure therapy is one of the best treatments available, as many as 25% of patients do not respond and we do not know why. Extinction learning is thought to be the mechanism of exposure therapy, and the neuroscience of extinction learning has advanced significantly since exposure therapy was developed; however, there has been little application towards improved clinical outcomes. This project aims to improve exposure therapy response for patients with social anxiety disorder by directly linking exposure therapy response to the neurobiology of extinction learning. It also aims to increase our scientific understanding of how brain circuits work to support extinction learning. To do this, 80 adults with social anxiety disorder will randomly be assigned to either receive exposure therapy right away, or to wait before therapy. Participants will all complete a functional magnetic resonance imaging scan to assess extinction learning before the therapy.


Clinical Trial Description

The best available treatment for social anxiety disorder is exposure therapy; however, 25% of socially anxious patients do not respond to an adequate course of exposure therapy and it is unclear why. Prior attempts to identify non-responders using clinical and demographic features have been largely unsuccessful, highlighting the need to examine constructs that are more closely tied to the mechanism of treatment (i.e., extinction learning and recall) and the organ of dysfunction (i.e., the brain). The neurobiology of extinction learning and recall is well understood from decades of animal and pre-clinical laboratory work, which has highlighted the importance of the amygdala, dorsal anterior cingulate cortex (dACC), and ventromedial prefrontal cortex (vmPFC). However, this knowledge has not been leveraged to improve exposure therapy response, despite the assumption that response relies on extinction learning and its successful recall. Thus, a critical long-term goal is to improve exposure therapy response by tailoring therapy based on the neurobiological profile of each patient. This project addresses that goal by directly linking neurobiological profiles of extinction learning and recall with clinical symptoms and therapy response. A major objective of this project is therefore to build a mechanistic predictive model of exposure therapy response based on the neurobiology of extinction learning and recall. To accomplish this goal, the investigators will recruit 80 adults with social anxiety disorder who will be randomized to 10 sessions of exposure-focused therapy or waitlist. The primary clinical outcome measure will be the Liebowitz Social Anxiety Scale (LSAS), a validated and widely used measure that assesses anxiety and avoidance symptoms. Pre-therapy, participants will also undergo an experimental protocol for extinction learning and recall. Participants will first view a neutral abstract image repeatedly paired with a loud aversive noise, and another image that is never paired (fear acquisition phase). Following this, participants will view the same images without aversive consequences (extinction learning phase). Better extinction learning will be defined as greater reductions in skin conductance within the extinction learning phase. Brain activation during extinction learning will be assessed in the amygdala, dACC, and vmPFC. Finally, participants will view the same images without aversive consequences one week later (extinction recall phase). Better extinction recall will be defined as less skin conductance during extinction recall relative to fear acquisition. The central hypothesis is that greater activation in the vmPFC during extinction learning will predict both extinction recall and therapy response over and above symptom severity. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03465137
Study type Interventional
Source Stanford University
Contact
Status Terminated
Phase N/A
Start date January 14, 2018
Completion date September 30, 2021

See also
  Status Clinical Trial Phase
Completed NCT05168020 - Evaluation of a Self-Monitoring Intervention to Reduce Safety Behavior in Social Anxiety N/A
Not yet recruiting NCT06020170 - Delving Into Participation Patterns in Social Anxiety Studies
Completed NCT03297619 - Self-help Books for Social Anxiety N/A
Completed NCT04509531 - Building Resilience in Cyberbullying Victims N/A
Recruiting NCT04859790 - Acceptability/Feasibility Testing of SCAR N/A
Completed NCT05576259 - oVRcome - Self Guided Virtual Reality for Social Anxiety Disorder N/A
Completed NCT05858294 - The Safety, Acceptability and Efficacy of Alena N/A
Completed NCT04450303 - Social Anxiety Telehealth Therapy Study N/A
Completed NCT03601377 - Attention Bias Modification Treatment in Social Anxiety N/A
Completed NCT03671577 - Building Closer Friendships in Social Anxiety Disorder N/A
Not yet recruiting NCT06081348 - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders Phase 2
Recruiting NCT05554718 - Evaluation of a Smartphone Application for Self-help for Social Anxiety N/A
Completed NCT02534948 - Feasibility Study of Mindfulness and Acceptance Based Group Therapy for Social Anxiety N/A
Completed NCT03249116 - Assessing Mechanisms of Anxiety Reduction in Animal-assisted Interventions N/A
Completed NCT05159037 - Using the Musical Track From GC-MRT as a Treatment Booster in Stressful Situations N/A
Completed NCT03711513 - Facing Fears by Focussing on Behaviour, Body, or Mind? N/A
Completed NCT04845100 - Animal Assisted Activities on the Stress and Social Anxiety N/A
Active, not recruiting NCT04276363 - Families, Children and Teachers Thriving Together N/A
Completed NCT05372744 - Affect-regulatory Characteristics of Deceptive Placebos N/A
Recruiting NCT05798078 - The Relationship Between Social Anxiety and Anxious Thinking Styles N/A